Using depot medroxyprogesteronacetate as a modern contraceptive method
Authors:
T. Fait
Authors‘ workplace:
1. LF UK a VFN Praha
; Gynekologicko-porodnická klinika
Published in:
Prakt Gyn 2010; 14(2): 93-95
Category:
Unreviewed Post
Overview
Depot medroxyprogesterone acetate is a progestin-only long-acting reversible hormonal contraceptive agent to be injected once every 3 months. Its newer form for subcutaneous application contains 104 mg of the drug only. It is characterized by high efficacy and safety, high percentage of amenorrhea and delayed return of fertility.
Key words:
depot medroxyprogesterone acetate – contraception
Sources
1. Jain J, Jakimiuk AJ, Bode FR et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70(1): 11–18.
2. Čepický P, Dvořák K, Dvořák V et al. Doporučení k předpisu gestagenní kontracepce, Čes Gynek 2001, 66(2):140–142.3. Koryntová D. Gestagenní kontracepce, Mod Gyn Por 2001; 10(2): 152–159.
4. Bigrigg A, Evans M, Gbolade B et al. Depo Provera. Position paper on clinical use, effectiveness and side effects. Br J Fam Plann 2000; 26(1): 52–53.
5. Cibula D, Henzl J, Zivny J. Základy gynekologické endokrinologie. Praha: Grada 2002: 340.
6. Guiloff E. Effect of contraception on lactation. AJOG 1974; 118: 42–45.
7. Huezo C, Carignan C. Medical and service delivery guidelines for family planning. London: IPPF 1997: 298.
8. Jain J, Dutton C, Nicosia A et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004; 70(1): 11–18.9. Petitti DB. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol 2000; 95(5): 734-744.
10. Naessen T, Olsson SE, Gudmundson J. Differential effects on bone density of progestogen- only methods for contraception in premenopausal women, Contraception 1995; 52(1): 35–39.
11. Berenson AB, Rickert VI, Grady JJ. A prospective study of effects of oral and injectable contraception on bone mineral density. Obstet Gynecol 2000; 95(Suppl.4): S6.
12. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesteron acetate, Contraception 2006; 73(6): 577–583.
13. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic para-metrs and mood changes. J Reprod Med 1996, 41(Suppl.5): S401–S406.
14. Bigriss A, Evans N, Gbodale B et al. Depo Ptovera. Position paper on clinical use, effectiveness and side effects, Br J Fam Plann 1999, 25(2): 69–76.
15. Kunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996; 41(Suppl 5): 419–427.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2010 Issue 2
Most read in this issue
- Gynaecological surgery techniques in female to male transsexualism.
- New approaches in the aesthetic surgery of female genitalia
- Hormonally-active tumours in differential diagnostics of precocious puberty in girls between 1973 and 2008
- Type 1 and 2 diabetes and pregnancy